Kymera Therapeutics Announces Sanofi IRAK4 Collaboration Update
Provided By GlobeNewswire
Last update: Jun 25, 2025
Sanofi to advance Kymera’s next-generation oral IRAK4 degrader development candidate, KT-485, into clinical testing and will not advance KT-474
In preclinical testing, KT-485 demonstrated increased selectivity and potency with a favorable safety profile
Read more at globenewswire.com
